{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 13 of 60', '13.7.1', 'Publication of Study Results', '55', '13.7.2', 'Clinical Study Report', '56', '14 References', '57', '15 Protocol Signature Pages', '59', '15.1 Sponsor Signature Page', '59', '15.2 Investigator Signature Page', '60', 'List of Tables', 'Table 2-1', 'Treatment Period Groups and Dosages', '3', 'Table 3-1', 'Study VX18-445-109: Screening', '6', 'Table 3-2', 'Study VX18-445-109: Treatment Period and Safety Follow-up Visit', '7', 'Table 9-1', 'Treatment Period Groups and Dosages', '20', 'Table 9-2', 'Prohibited Medications', '25', 'Table 10-1', 'Study Drug: Strength/Dosing Form/Route', '30', 'Table 11-1', 'Safety Laboratory Test Panels', '36', 'Table 11-2', 'Acceptable Methods of Contraception', '39', 'Table 13-1', 'Grading of AE Severity', '49', 'Table 13-2', 'Classifications for AE Causality', '49', 'Table 13-3', 'Classifications for Study Drug Action Taken With Regard to an AE', '50', 'Table 13-4', 'Classifications for Outcome of an AE', '50', 'List of Figures', 'Figure 2-1', 'Schematic of the Study Design', '3', 'Figure 9-1', 'Schematic of the Study Design', '20', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 14 of 60', 'List of Abbreviations', 'Abbreviation', 'Definition', 'AE', 'adverse event', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine transaminase', 'AST', 'aspartate transaminase', 'CF', 'cystic fibrosis', 'CFQ-R', 'Cystic Fibrosis Questionnaire-Revised', 'CFTR', 'CF transmembrane conductance regulator protein', 'CFTR', 'CF transmembrane conductance regulator gene', 'CI', 'confidence interval', 'CRF', 'case report form', 'CSR', 'clinical study report', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CYP', 'cytochrome P450', 'ECG', 'electrocardiogram', 'EDC', 'electronic data capture', 'EENT', 'eyes, ears, nose, and throat', 'ETT', 'Early Termination of Treatment', 'EU', 'European Union', 'F/F', 'homozygous for the F508del CFTR mutation', 'F/MF', 'heterozygous for the F508del and a minimal function CFTR mutation', 'F508del', 'CFTR gene mutation with an in-frame deletion of a phenylalanine codon', 'corresponding to position 508 of the wild-type protein', 'FAS', 'Full Analysis Set', 'FDA', 'Food and Drug Administration', 'FDC', 'fixed-dose combination', 'FEF25%-75%', 'forced expiratory flow, midexpiratory phase', 'FEV1', 'forced expiratory volume in 1 second', 'FSH', 'follicle-stimulating hormone', 'FVC', 'forced vital capacity', 'GCP', 'Good Clinical Practice', 'GGT', 'gamma-glutamyl transferase', 'GLI', 'Global Lung Function Initiative', 'GPS', 'Global Patient Safety', 'HR', 'heart rate', 'IA', 'interim analysis', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonization', 'ICMJE', 'International Committee of Medical Journal Editors', 'IDMC', 'independent data monitoring committee', 'IEC', 'independent ethics committee', 'IPD', 'important protocol deviation', 'IRB', 'institutional review board', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 15 of 60', 'IVA', 'ivacaftor', 'IWRS', 'interactive web response system', 'LS', 'least squares', 'LUM', 'lumacaftor', 'max', 'maximum value', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'min', 'minimum value', 'MMRM', 'mixed-effects model for repeated measures', 'OATP1B1/3', 'organic anion transporting polypeptide 1B1/3', 'P', 'probability', 'PD', 'pharmacodynamics', 'PE', 'physical examination', 'PEx', 'pulmonary exacerbation', 'p-gp', 'P-glycoprotein', 'ppFEV1', 'percent predicted forced expiratory volume in 1 second', 'PR', 'PR interval, segment', 'PT', 'Preferred Term', 'q12h', 'every 12 hours', 'qd', 'once daily', 'QRS', 'the portion of an ECG comprising the Q, R, and S waves, together representing', 'ventricular depolarization', 'QT', 'QT interval', 'QTcF', \"QT interval corrected by Fridericia's formula\", 'RR', 'interval from the onset of 1 QRS complex to the next; use R-R if using with', '\"intervals\", i.e., \"R-R interval\"', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SD', 'standard deviation', 'SOC', 'System Organ Class', 'SUSAR', 'suspected, unexpected, serious adverse reaction', 'SwCl', 'sweat chloride', 'TC', 'triple combination', 'TE', 'treatment-emergent', 'TEAE', 'treatment-emergent adverse event', 'TEZ', 'tezacaftor', 'ULN', 'upper limit of normal', 'US', 'United States', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}